ESMO24 Day 1 highlights by Tom Powles

The ESMO Congress 2024 (ESMO24) is taking place from 13-17 September 2024, in Barcelona.

ESMO24 is one of the most globally influential platforms in oncology, bringing together clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from across the world.

It is held through a Virtual Congress Platform, ESMO24 will serve as a critical hub for the dissemination of the latest cutting-edge cancer research, offering high-quality education and dynamic networking opportunities.

Tom Powles, Director of Barts Cancer Centre, shared some insights from ESMO24.

PEACE3, an investigator trial

Presidential for Silke Gillessen, Uromigos, ESMO2024. Radium223 enza vs enza alone shows a PFS and OS advantage in metastatic CRPC. PEACE3 is an investigator trial and rejuvenates radium-223 in prostate cancer. 0.69 HR for PFS and OS !!!

Phase 1/2 Design of the HIF2a inhibitor NKT2152-101

Phase 1/2 Design of the HIF2a inhibitor NKT2152-101 showed response rate of 20% with an ‘in class’ toxicity profile ESMO24 . The long half like makes it distinct and there in now a dose to take to randomised trials. Advantages over belzurifan are unclear. 2 doses being pursued.

HER3 EGFR Topo-1 ADC showing unconfirmed responses

HER3 EGFR Topo-1 ADC shows unconfirmed responses of 40%. The numbers are small but the MOA is novel and the data looks good. Adverse events are driven by Topo-1 toxicity. This agent is exciting should be further investigated alone and in combination in randomised trials.

Therapy in advanced non-clear cell renal cancer

SUNNIFORCAST ipi/nivo vs VEGF based therapy in advanced non-clear cell renal cancer. +ve 12 month OS,OS HR 0.86, increased RR but -ve PFS. Uncertainty around papillary subgroup & mixed control arm. But PD-1 based therapy looks like the backbone of future therapy. PD-L1 biomarker?

Belzutifan vs Everolimus

Belzutifan vs everolimus showed increased RR and PFS but not significant OS, ESMO2024 . Despite this lack of OS belzutifan looks as good as sequencing other VEGF TKI therapy, but with a nice toxicity signal. The ESMO guidelines group gave it a strong recommendation especially 3rd line.

Pretreated M1 renal cancer

Tivozanib +/- nivolumab in IO pretreated M1 renal cancer showed retreatment with IO makes absolutely no difference. This is on top of CONTACT3 which showed the same thing.We need to stop retreating with IO.These data apply in the post adjuvant setting too without data.

For more updates on ESMO24, visit oncodaily.com